Health Care · Pharmaceutical Preparations

CYTK CYTOKINETICS INC SEC Filings & Insider Trading Activity 2026

company
CIK 1061983168 filings
Russell 2000

CYTK at a glance

CYTOKINETICS INC (CYTK, SEC CIK 1061983) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CYTOKINETICS INC (CYTK) reported revenue of $88.0 million (up 376.6% from FY2024) and a net loss of $785.0 million. Diluted EPS was -$6.54.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding CYTOKINETICS INC (CYTK) shares worth $4.2 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Hessekiel Jeffrey on November 17, 2026 of 15,106 shares at $52.62 per share.
  • In the last 90 days, CYTK insiders reported 0 open-market purchases ($0) and 23 open-market sales ($13.3M) on Form 4, a net sale of $13.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$88.0M
+376.6% vs prior year
Insiders · 90 days
0 buys · 23 sells
Net −$13.3M
13F holders
32 funds
$4.2B · −1 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: biopharmaceutical development and commercialization focused on muscle biology therapeutics for cardiovascular diseases
  • New product launch: MYQORZO approved by FDA in Dec 2025 for symptomatic oHCM, first commercial sales commenced Q1 2026
  • Strategic shift: transition from R&D focus to commercial readiness and sales activities for MYQORZO in US and Europe
  • Financial metric: cash, cash equivalents, and marketable securities $1.22B (2025), borrowings increased to $1.33B from $805M in 2024
  • Noteworthy fact: entered multiple substantial royalty monetization and debt financings including $750M 2031 Notes issuance and renegotiated out-licenses in Greater China and Japan

Risk Factors

  • Cybersecurity risk oversight led by Audit Committee with tech, risk, finance expertise and regular briefings from CISO, CEO, CFO
  • Dependence on Chief Information Security Officer Eric Brown with 10+ years cybersecurity experience for managing critical security operations
  • Cybersecurity incident response plan includes immediate impact mitigation and long-term remediation strategies
  • Ongoing Board and Audit Committee dialogue on emerging cybersecurity threats ensures proactive risk governance
  • No specific regulatory, geopolitical, operational supply chain, competitive, or financial risks detailed in this section

Management Discussion & Analysis

  • Revenue $88.1M in 2025, up $69.6M from $18.5M in 2024, driven by license and milestone revenues from Bayer and Sanofi
  • Operating expenses rose sharply: R&D $416.0M (+23% YoY), G&A $284.3M (+32% YoY), reflecting clinical advancement and commercial readiness
  • Best segment license/milestone revenues $79.4M in 2025 vs $15.0M in 2024; collaboration revenue $8.7M in 2025 vs $3.5M in 2024
  • Cash use in 2025 driven by $100M loan draw, $121.2M debt conversion expense, increased interest expense $45.6M (up $7.9M YoY); expect higher SG&A in 2026 due to commercialization
  • Management expects flat to declining R&D in 2026; key risks: regulatory approvals, market acceptance of MYQORZO, limitations from FDA partial clinical hold on CK-089 trial

AI summary of the CYTK 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New regulatory risk: August 2026 ACACIA-HCM results may not support aficamten approval for nHCM
  • Most material update: Planned supplemental NDA submission in fourth quarter 2026 after positive dual primary endpoints
  • FDA review risk: Left ventricular ejection fraction below 50% occurred more frequently with aficamten
  • Competitive risk: Camzyos failed both dual primary endpoints in ODYSSEY-HCM for nHCM
  • Commercial risk: Delayed or limited approval could prevent nHCM commercialization on the anticipated timeline

Management Discussion & Analysis

  • Q3 revenue $47.6M, up $45.6M YoY, driven by MYQORZO product revenue of $44.5M
  • Q3 operating expenses $214.6M, up $46.0M YoY, including SG&A of $113.1M
  • Best-performing product line: MYQORZO U.S. revenue $43.1M, Europe $1.4M
  • Cash, cash equivalents and securities $1.58B, up from $1.22B at December 31, 2025
  • Nine-month operating cash outflow $429.3M, financing inflow $805.4M including $760.1M public-offering proceeds

AI summary of the CYTK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management disclosures available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $47.6M, including $44.5M MYQORZO sales, signals commercial launch traction versus $1.9M total revenue in Q3 2025
  • MYQORZO adoption reached nearly 1,100 prescribers and over 2,800 dispensed patients, supporting continued U.S. growth and international expansion
Filed Aug 28, 2026Full analysis →

Item 8.01: Other Events

  • ACACIA-HCM full results presented at ESC Congress 2026, increasing visibility among cardiology specialists and investors
  • Results published in the New England Journal of Medicine, providing peer-reviewed validation of the study
Filed Aug 13, 2026Full analysis →

Item 8.01: Other Events

  • Cytokinetics filed a Delaware lawsuit against Bristol-Myers Squibb and MyoKardia over U.S. Patent No. 12,616,697
  • Declaratory judgment seeks findings that MYQORZO (aficamten) does not infringe and the patent claims are invalid

AI summaries of CYTK 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CYTK

Don't miss the next CYTK filing

  • Alerts as it files. A push when CYTK files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CYTK, by share count.
  • Ask anything. An AI agent that reads every CYTK filing and answers with sources.

CYTK alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Hessekiel JeffreySellNov 17, 2026$52.62
Malik Fady IbrahamMNov 17, 2026-
Malik Fady IbrahamSellNov 17, 2026$51.73
Malik Fady IbrahamSellNov 17, 2026$52.59
Malik Fady IbrahamMNov 17, 2026$7.80
Blum Robert IMNov 16, 2026$10.60
Blum Robert ISellNov 16, 2026$53.22
Blum Robert ISellNov 16, 2026$54.08

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$18.5M$88.0M
Operating Income--$536.2M-$612.3M
Net Income-$526.2M-$589.5M-$785.0M
Op. Margin--2902.7%-695.4%
Net Margin--3191.1%-891.6%
Balance Sheet
Total Assets-$1.4B$1.4B
Equity-$386.3M-$135.4M-$659.6M
ROE136.2%435.5%119.0%
Per Share
EPS$-5.45$-5.26$-6.54
Cash Flow
Operating CF--$395.9M-$510.0M
CapEx$1.4M$3.9M$24.8M

Source: XBRL data in CYTOKINETICS INC (CYTK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CYTK share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CYTK shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$4.22B
Q2 202633$5.61B
Q1 202633$4.04B
Q4 202530$4.10B
Q3 202529$3.62B
Q2 202528$2.01B
Q1 202527$1.68B
Q4 202424$1.69B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 236 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CYTK filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 12, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Nov 3, 2026--
4Nov 2, 2026--
4Oct 20, 2026--
4Oct 20, 2026--
4Oct 20, 2026--
4Oct 20, 2026--
4Oct 20, 2026--
4Oct 20, 2026--
4Oct 20, 2026--
4Oct 13, 2026--
4Oct 6, 2026--
4Sep 28, 2026--
4Sep 22, 2026--
4Sep 15, 2026--
4Sep 15, 2026--
4Sep 11, 2026--
4Sep 8, 2026--
4Sep 1, 2026--
4Aug 31, 2026--

Related Health Care companies

All Health Care →

CYTK SEC filings: frequently asked questions

Are CYTK insiders buying or selling?

In the last 90 days, CYTOKINETICS INC (CYTK) officers, directors and 10% owners reported no open-market purchases and 23 open-market sales worth $13.3 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CYTK stock?

As of September 30, 2026, the largest CYTOKINETICS INC (CYTK) holders among the 13F filers tracked by SignalX were BlackRock ($1.4 billion), State Street Corp ($470.8 million), Vanguard Portfolio Management LLC ($448.2 million), Vanguard Capital Management LLC ($413.0 million), Bank of America Corp ($312.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CYTK's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CYTOKINETICS INC (CYTK) reported revenue of $88.0 million (up 376.6% from FY2024) and a net loss of $785.0 million. Diluted EPS was -$6.54. The figures come from the XBRL data in the 10-K.

What are the main risks in CYTK's latest 10-K?

In the 10-K filed February 26, 2026, CYTOKINETICS INC (CYTK) flagged: Cybersecurity risk oversight led by Audit Committee with tech, risk, finance expertise and regular briefings from CISO, CEO, CFO. Dependence on Chief Information Security Officer Eric Brown with 10+ years cybersecurity experience for managing critical security operations. (AI summary of the Risk Factors section.)

What did CYTK report in its latest 8-K?

CYTOKINETICS INC (CYTK) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest CYTK SEC filings?

CYTOKINETICS INC (CYTK) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 18, 2026.

What is CYTK's SEC CIK number?

CYTOKINETICS INC (CYTK)'s SEC Central Index Key (CIK) is 1061983. EDGAR lists every CYTK filing under that number.

Ask anything about CYTK

The research agent reads CYTK's filings, financials, insider trades and 13F holders, then answers with sources.